OKLO · Oklo Inc. · Stock research

Current Thesis

The two undated items this coverage has been tracking since 2026-07-23 both resolved inside 48 hours, and the tape separated them cleanly.

Groves first criticality — targeted for July 2026, restated in the 2026-07-23 DOE Startup Authorization release, then silent for two weeks — was announced on 2026-08-06. The Q2 deck dates the event to early August. The market's answer to the reactor itself was a flat 2026-08-06 session closing $42.19.

The answer to the numbers was different. Q2 revenue printed $1.210M against a $126,250 consensus (Benzinga, 2026-08-07); adjusted EPS was -$0.28 against -$0.16. Liquidity stood at $3.0B at quarter-end, $1.6B cash and $1.4B marketable securities, versus $2.54B at 2026-03-31. Management raised 2026 operating cash use to $120–150M from $80–100M and capex to $400–500M from $350–450M, framing it as pulling projects forward.

The narrative leg being bought here is execution credibility: a developer that went from groundbreaking to a self-sustaining chain reaction in 11 months, with 229 days of substantial construction completion, now claiming the same cadence for Aurora-INL at a 2028 startup target and isotope revenue from the Idaho Radiochemistry Laboratory in early 2027.

The prior note's $38.83 daily-close condition was never met. The pullback bottomed at the 2026-07-29 close of $36.84, against a $36.61 52-week low.

Narrative life-cycle: ACCELERATING — dated 2026-08-07, when an Oklo-specific disclosure produced the largest single-session move and the heaviest volume of the window and carried price above the 2026-07-23 high of $44.59 for the first time. That reverses the prior note's DEAD reading, which rested on company milestones failing to move the stock. The reversal rests on two sessions, and the flat 2026-08-06 close on criticality itself says the re-link runs through financial disclosure rather than through hardware.

Bullish and bearish views on Oklo Inc.

The model's bull view on Oklo Inc. (OKLO), in brief: Groves reached first criticality in under 11 months from groundbreaking, with substantial construction completion in 229 days, described on the 2026-08-07 call as the fastest privately funded greenfield reactor to criticality. The bear view: Dilution is the funding mechanism, and it is running at scale: $1.9B of ATM proceeds raised during 2026, disclosed on the 2026-08-07 call. Both cases follow in full.

Bull Case

• Groves reached first criticality in under 11 months from groundbreaking, with substantial construction completion in 229 days, described on the 2026-08-07 call as the fastest privately funded greenfield reactor to criticality. The 2022 NRC denial and the 2026-01-07 Meitner-1 withdrawal made delivery the open question; a reactor that went critical is a different evidentiary base than a permit application.
• First revenue exists. Q2 sales of $1.210M cleared a $126,250 consensus (Benzinga, 2026-08-07), removing the pre-revenue label the prior note carried.
• Balance sheet is not the near-term constraint: $3.0B cash and marketable securities at 2026-06-30, generating $44.5M of interest and dividend income in H1 2026 against an H1 net loss of $81.6M.
• CFO Craig Bealmear characterised demand as "in a sense, unconstrained."

• Published sell-side marks sit above the tape. Barclays maintained Overweight on 2026-07-23 while cutting to $76; the prior note recorded S&P Global consensus of $84.20 across 25 analysts as of 2026-08-04.

Bear Case

• Dilution is the funding mechanism, and it is running at scale: $1.9B of ATM proceeds raised during 2026, disclosed on the 2026-08-07 call. Shares outstanding stand at 186.02M. The $1.0B program from the 2026-05-13 424B5 follows a prior facility drawn roughly $1.499B.
• The raised capex guide of $400–500M for 2026, against H1 capex of $126.9M, implies a second-half spend rate that the ATM has historically funded.
• Adjusted EPS missed at -$0.28 versus -$0.16. H1 operating cash flow was -$65.5M.
• Insiders sold into the low of the move four days before the beat: DeWitte and Cochran each sold roughly 120,000 Class A shares on 2026-08-03 across six tranches apiece at $38.55–$41.68, under Rule 10b5-1 plans adopted 2025-03-31. The next monthly tranche falls due on or about 2026-09-01, now roughly 15% higher.
• $1.210M of quarterly revenue against a $9.01B market capitalisation at the 2026-08-07 close means the valuation rests entirely on 2028-and-later deployment.
• No combined licence application timing for commercial Aurora licensing was given in the Q2 materials; the NRC path remains pre-application after the 2022 denial.

Setup & Price Structure

• The 2026-07-23 high of $44.59 capped every cohort-driven bounce in the prior window. It was taken out on the print.
• The open gap runs $42.19 to $48.42. Nothing traded inside it, so it is the cleanest structural reference on the chart.
• Extension: the 2026-08-07 close is roughly 31% above the 2026-07-29 close, achieved in seven sessions. Price remains about 75% below the $193.84 52-week high, so overhead supply from 2025 holders sits far above.
• Crowding observables, stated as observables: a two-week-lagged short reading of 18.39% of float; a 22.1M-share session versus the ~8.5M of 2026-08-04; recurring first-of-month founder supply under 10b5-1; $1.9B of ATM issuance already executed in 2026; retail-facing coverage clustering on 2026-08-07 headlines.

Catalyst Calendar (next 30 days)

• ~2026-08-11 (est.) — Q2 2026 Form 10-Q, if not filed alongside the 2026-08-07 release. Carries the cover-page share count and the equity-issuance footnote behind the $1.9B ATM figure.
• ~2026-08-12 (est.) — FINRA semi-monthly short interest, 2026-07-31 settlement. Covers the pre-criticality bounce only.
• 2026-08-14 — Q2 2026 13F deadline. Shows which institutions added or cut through the quarter that took the stock from the $60s to $36.61.
• ~2026-08-26 (est.) — FINRA short interest, 2026-08-14 settlement. First reading that spans criticality and the print.
• ~2026-09-01 (est.) — Next monthly founder tranche under the 10b5-1 plans, on the 2026-06-01 / 2026-07-01 / 2026-08-03 cadence.

Elapsed catalysts

• ~2026-Q3 (est.) — Holtec Nuclear IPO pricing on Nasdaq under HNUC; S-1 publicly filed 2026-07-10, no range set as of 2026-08-07. (passed 2d ago)

What Would Change Our Mind

The structure that now defines the read is the unfilled 2026-08-07 gap between $42.19 and $48.42. Filling it would mean the market re-priced criticality and first revenue back to where it had them before either was known — a daily close below $42.19 is the gradeable form of that.

Three other observables would flip the reading independently of price. First, the ~2026-08-26 short-interest release showing a large decline in the short book while price stalls beneath $48.42, which would attribute the print reaction to covering rather than to new demand. Second, a fresh 424B5 or a Q3 share count materially above 186.02M, confirming the raised $400–500M capex guide is being funded by issuance at prices well under the levels at which earlier facilities cleared. Third, the ~2026-09-01 founder tranche executing into the recovery with no offsetting Form 4 purchases, which would keep the 400,000-share monthly supply pattern intact at higher prices.

The bull case correspondingly strengthens if Aurora-INL draws a docketed NRC combined licence application date, or if the Meta and Centrus arrangements convert into a disclosed contracted-revenue figure — neither of which appeared in the Q2 materials.

Correlation Notes

• OKLO trades with the SMR/fuel-cycle cohort on most sessions. On 2026-08-04 NuScale rose 4.1% and Centrus 8.0% against OKLO's 5.12%; on 2026-08-03 NuScale rose 6.95% against OKLO's 6.16%. The 2026-08-07 session broke that pattern, with the move driven by Oklo's own release.
• The AI-datacenter-power bid links the name to policy headlines rather than to fundamentals: OKLO and X-Energy both jumped on 2026-07-21 on the Bloomberg report of the federal program to accelerate reactors for AI data centres.
• The Holtec IPO (HNUC, S-1 filed 2026-07-10) competes for the same theme allocations with a revenue-generating profile, and its pricing would set a market-clearing comparable for the group.
• Rate direction cuts both ways: $44.5M of H1 interest and dividend income is a real line that shrinks if yields fall, while a lower discount rate supports a 2028-cash-flow equity.
• The float is small relative to attention — 186.02M shares outstanding with an 18.39%-of-float short reading at 2026-07-15 — so cohort headlines translate into outsized single-session moves in both directions.